By DAN MCGOWAN Writer/Reporter, Inside Indiana Business A potential rheumatoid arthritis treatment being co-developed by Indianapolis-based Eli Lilly and Co. and Incyte Corp. continues to return positive results in late-stage testing. In a recent phase-three global study, Lilly says baricitinib met its primary endpoint. The results have been published in the New England Journal of Medicine. Lilly’s …read more.